Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 12/20 | 0.52 |
| ▸ | BCR | P11274 | 7/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | BRAF | P15056 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | RAF1 | P04049 | 2/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | BTK | Q06187 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6450306 | 0.90 | BTK (0.54) | SCN9ABRAFMAPK14RAF1BTK | |
| SCHEMBL6454154 | 0.88 | BRAF (0.52) | BRAFRAF1BTK | |
| SCHEMBL6461342 | 0.86 | EGFR (0.51) | MAPK14 | |
| SCHEMBL6454592 | 0.83 | MAPT (0.52) | BTK | |
| SCHEMBL6454347 | 0.82 | MAPT (0.49) | RAF1 | |
| SCHEMBL5863233 | 0.74 | HDAC8 (0.62) | ABL1KCNH2 | |
| SCHEMBL5031557 | 0.73 | MAPT (0.56) | — | |
| SCHEMBL4884795 | 0.72 | MAPT (0.61) | MAPK14BTK | |
| SCHEMBL4414154 | 0.72 | ABL1 (0.71) | ABL1BCR | |
| SCHEMBL4884549 | 0.71 | MAPT (0.68) | ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159391-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-07-21 | — | — | US | claimed |
| US-20080108616-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-05-08 | — | — | US | disclosed |
| US-20080108616-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-05-08 | — | — | US | disclosed |
| US-7338957-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-03-04 | — | — | US | disclosed |
| US-7338957-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2008-03-04 | — | — | US | disclosed |
| US-20050159391-A1 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2005-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108616-A1 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | LCK, FYN, BMX | ABL1 53/4885BCR 64/4885KCNH2 3648/4885 |
| US-20050159391-A1 | Compounds and compositions as protein kinase inhibitors | LCK, FYN, BMX | ABL1 53/4885BCR 64/4885KCNH2 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.